Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of triterpenoid saponins compound

A technology of triterpene saponins and compounds, applied in the field of medicine

Active Publication Date: 2017-01-25
JIANGSU KANION PHARMA CO LTD
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The drug effect and application of the anti-asthma involved in the present invention have not been reported yet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of triterpenoid saponins compound
  • Application of triterpenoid saponins compound
  • Application of triterpenoid saponins compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Example 1 Ecliptasin A, B, C and D inhibit activity of platelet activating factor receptor (PTAFR)

[0058] 1. Experimental materials:

[0059] 1.1 Cell line: The cell line CHO-K1 stably transfected with PTAFR was constructed by Jiangsu Kangyuan Pharmaceutical Co., Ltd.

[0060] 1.2 Main reagents: F12 medium and fetal bovine serum were purchased from Hyclone Company; Zeocin and HBSS were purchased from Invitrogen Company; calcium flux detection kit was purchased from Molecular Device Company; PAF (C16), WEB2086 were purchased from tocris; HEPES was purchased from Nanjing Shengxing Biotechnology Co., Ltd.; DMSO was purchased from sigma;

[0061] 1.3 Instruments: FLIPR tetra microplate reader, Molecular Devices; pipette, eppendorf; ultra-clean bench, purchased from Shanghai Jiejia Air Purification Technology Co., Ltd.; CDX-K1 inverted microscope, purchased from Olympus; countess The automatic cell counting instrument was purchased from Invitrogen Company; the 3111 cell ...

Embodiment 2

[0080] Embodiment 2Eclipta glucoside A, B, C and D are to the influence of bronchial asthma rat model

[0081] 1. Experimental materials:

[0082] 1.1 Animals: clean grade SD rats, all male, with a body weight of 260±20g, from Qinglongshan Animal Breeding Farm.

[0083] 1.2 Main reagents: Ovalbumin (OVA) was purchased from Sigma Company; Dexamethasone Sodium Phosphate Injection (5 mg / m1) was purchased from Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.

[0084] 1.3 Instruments: Powerlab / 8sp' physiological signal acquisition system, purchased from Ed Instruments International Trade (Shanghai) Co., Ltd.; LDZ5-2 centrifuge, purchased from Beijing Jingli Centrifuge Co., Ltd.; M2e microplate reader, purchased from MolecularDevices Company; medical ultrasonic atomization inhaler, Shanghai Medical Equipment Factory.

[0085] 2. Experimental method:

[0086] 2.1 Preparation of asthma model: 1ml of 10% OVA, 100mg of aluminum hydroxide dry powder, inactivated Bacillus pertuss...

Embodiment 3

[0096] The effect of embodiment 3 Eclipta glucoside A, B, C and D on the therapeutic effect of asthmatic guinea pig GM-CSF and PAF

[0097] 1. Experimental materials:

[0098] 1.1 Animals: 120 healthy male variegated guinea pigs, body weight 350-450g, Qinglongshan Animal Breeding Farm. 1.2 Main reagents: Ovalbumin (OVA) was purchased from sigma; GM-CSF detection kit was purchased from Shanghai Kexing Biotechnology Company; PAF ELISA detection kit was purchased from Shanghai Meixuan Biotechnology Co., Ltd.; positive control drug Aminophylline tablet, specification: 0.1g / sheet, product of Shanxi Yunpeng Pharmaceutical Co., Ltd.

[0099] 1.3 Instruments: LDZ5-2 centrifuge, purchased from Beijing Jingli Centrifuge Co., Ltd.; M2e microplate reader, purchased from Molecular Devices; medical ultrasonic atomizing inhaler, Shanghai Medical Device Factory.

[0100] 2. Experimental method:

[0101] 2.1 Model replication and drug administration 120 guinea pigs were randomly divided int...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines and in particular relates to application of a triterpenoid saponins compound. The invention provides application of the triterpenoid saponins compound with a structure formula I to preparation of a medicine for treating asthma. An experiment testifies that the triterpenoid saponins compound with the structure formula I has an obvious inhibition effect on a platelet activating factor receptor and can be used for alleviating tachypnea and accelerated frequency, caused by the asthma, and remarkably reducing the amount of Eos (Eosinophile granulocyte) in rat blood and reducing infiltration on trachea by the Eos; meanwhile, the secretion of GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) in BALF (Bronchoalveolar Lavage Fluid) of guinea pigs can be inhibited and a PAF (Platelet-Activating Factor) level of blood serum of the guinea pigs is remarkably reduced, and the activation of inflammatory cells and the releasing of inflammatory transmitters are stopped, so that inflammation of the trachea is alleviated and smooth muscles of bronchus are relaxed; the high responsiveness of the trachea is reduced to treat the asthma, so that the triterpenoid saponins compound has the effect of treating the asthma and application value.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of triterpene saponin compounds. Background technique [0002] Bronchial asthma (abbreviation asthma) is a kind of common respiratory disease. Clinically, the main manifestations are recurrent wheezing, shortness of breath, chest tightness, coughing and other symptoms. A small number of patients may also experience chest pain. In severe cases, dyspnea and sudden death may occur. Asthma is one of the most common chronic diseases worldwide, and its prevalence has been increasing year by year in recent years. The pathogenesis of asthma is complicated, and there is no complete cure for it at present, and the effect of existing drugs is limited, so it is of great significance to develop new drugs for the treatment of asthma. [0003] In the past, asthma was considered to be an airway obstructive disease caused by smooth muscle spasm, but the current view is that ast...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61P11/06
CPCA61K31/704
Inventor 萧伟陶晓倩王俨如曹亮王振中丁岗胡晗绯
Owner JIANGSU KANION PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com